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Abstract 
Accumulated evidence indicates that cytotoxic function of immune effectors is largely 
suppressed in the tumor microenvironment by a number of distinct effectors and their 
secreted  factors.  The  aims  of  this  review  are  to  provide  a  rationale  and  a  potential 
mechanism for immunosuppression in cancer and to demonstrate the significance of 
such immunosuppression in cellular differentiation and progression of cancer. To that 
end, we have recently shown that NK cells mediate significant cytotoxicity against pri-
mary oral squamous carcinoma stem cells (OSCSCs) as compared to their more differen-
tiated oral squamous carcinoma cells (OSCCs). In addition, human embryonic stem cells 
(hESCs), Mesenchymal Stem Cells (hMSCs), dental pulp stem cells (hDPSCs) and in-
duced pluripotent stem cells (hiPSCs) were all significantly more susceptible to NK cell 
mediated cytotoxicity than their differentiated counterparts or parental cells from which 
they were derived. We have also reported that inhibition of differentiation or reversion of 
cells to a less-differentiated phenotype by blocking NFB or targeted knock down of 
COX2 in primary monocytes in vivo significantly augmented NK cell function. Total 
population of monocytes and those depleted of CD16(+) subsets were able to substan-
tially prevent NK cell mediated lysis of OSCSCs, MSCs and DPSCs. Taken together, our 
results suggest that stem  cells are significant targets of the NK cell cytotoxicity. The 
concept of split anergy in NK cells and its contribution to tissue repair and regeneration 
and in tumor resistance and progression will be discussed in this review. 
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Introduction 
Effective  immunosurveillance  is  important  for 
the prevention of initiation and progression of cancer. 
Rapid  progression  of  oral  leukoplakia  to  carcinoma 
was  previously  observed  after  immunosuppression 
[1]. Furthermore, neoplasias of tongue and lip have 
been  widely  described  in  renal  transplant  patients 
[2-5], and finally induction of oral cavity cancers was 
second to liver cancer in patients after bone marrow 
transplantation  [6].  In  addition,  there  is  substantial 
evidence which indicates that immune responses are 
inhibited by oral tumors, and this may largely be re-
sponsible  for  their  induction  and  progression.  This 
review will focus on the emerging new roles of NK 
cells in regulation of numbers, resistance and differ-
entiation of cancer stem cells as well as healthy un-
transformed stem cells. In addition, the significance 
and the role of anergic NK cells will be discussed in 
induction of tumor resistance, as well as in shaping 
the size and differentiation of healthy stem cells. 
Immunosuppression  and  tumor  escape  from 
immune recognition are thought to be major factors 
responsible for the establishment and progression of 
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cancer,  however,  neither  underlying  physiological 
significance nor the exact mechanisms by which im-
munosuppression  occurs  are  well  understood.  A 
number of factors responsible for the suppression of 
NK  cell  cytotoxicity  in  humans  has  been  identified 
previously  [7-12].  It  is  shown  that  freshly  isolated 
tumor infiltrating NK cells are not cytotoxic to autol-
ogous tumors. Moreover, NK cells obtained from the 
peripheral blood of patients with cancer have signifi-
cantly reduced cytotoxic activity [13-16]. In addition, 
NK cell cytotoxicity is suppressed after their interac-
tion with stem cells [17-19]. In contrast, interaction of 
NK cells with the resistant tumors leads to a much 
lower  suppression  of  NK  cell  cytotoxicity  when 
compared to those dissociated from the NK sensitive 
target cells [20, 21]. 
Many mechanisms have been proposed for the 
functional inactivation of tumor associated NK cells 
including the over-expression of Fas ligand, the loss of 
mRNA for granzyme B [8] and decreased CD16 and 
its associated zeta chain [22] (Table I).  
 
Table I. Mechanisms of immune evasion by tumor cells  
Defect  Mechanism  References 
Loss of T cell Recognition  Decreased MHC class I expression/shedding of class I; decreased TCR 
zeta chain expression, expression of co-stimulatory molecules (B7H1) 
on tumor cells 
[8, 29, 103, 104] 
Altered NK cell recognition  Decreased expression of NK receptor (NKG2D) ligands, increased 
MHC class I expression, decreased expression of adhesion molecules, 
CD16 and zeta chain 
[22, 29, 105, 106] 
Loss of NK cell function  Induction of anergy in NK cells. Activation of upstream transcription 
factors (NFB) in differentiated tumors and tumor cell production of 
inhibitory factors (IL-10, IL-6, IL-1 PGE2, GM-CSF, IL-8). Decreased 
IFN- secretion by the NK cells when co-cultured with increased NFB 
function in tumors 
[20, 21, 26, 29, 57, 
58, 60, 61, 92, 96-99, 
107-110] 
Enhanced tumor cell survival/resistance to 
killing 
Expression of anti-apoptotic molecules by tumor cells via activation of 
upstream transcription factors (c-Myc, AP-1, NFB, STAT3) 
[111-116] 
Increased NK and T cell apoptosis  TNF- induced apoptosis, Fas ligand expression by tumor cells and 
membranous vesicles; Fas-mediated apoptosis of responding T cells, 
expression of DF3 and Muc1 in tumor cells 
[10, 56, 117, 118] 
Inhibition of macrophage/DC maturation 
and function 
Tumor cell production of inhibitory cytokines (VEGF, IL-6, GM-CSF) 
and activation of STAT3-mediated transcription in DCs. 
[58, 62-64, 72, 107, 
119-126] 
Inhibition of T cell chemotaxis to tumor mi-
croenvironment 
Constitutive STAT3 activation in tumor cells, decreased expression of T 
cell chemotactic factors (RANTES, IP-10) 
[72] 
Increased recruitment or function of 
CD14+HLADR-monocytes,Tumor-associated 
Macrophages, MDSCs, Cancer Associated 
Fibroblasts, MSCs, Tregs and DCregs  
Suppression of cytotoxic immune effectors  [66, 67]; [68, 69]; 
[70] 
 
 
Many  metastatic  tumor  cells  exhibit  constitu-
tively  elevated  NFB  activity  [23].  We  have  previ-
ously shown that NK resistant primary oral epithelial 
tumors demonstrate higher nuclear NFB activity and 
secrete  significant  levels  of  Granulocyte  Mono-
cyte-Colony  Stimulating  Factor  (GM-CSF),  Interleu-
kin(IL)-1β, IL-6 and IL-8 [24, 25]. Moreover, the addi-
tion  of  Non-steroidal  anti-inflammatory  drugs 
(NSAIDs) which inhibit NFB have the ability to re-
verse  immunosuppression  induced  by  a  tobac-
co-specific  carcinogen  [26]  in  addition  to  their 
well-established ability to decrease oral dysplasia as 
well as  induction of  overt oral cancer in transgenic 
animals [27]. The significance and exact mechanisms 
by which NFB nuclear function in oral tumors mod-
ulate and shape the function  of key interacting im-
mune effectors is starting to unravel. We have previ-
ously shown that inhibition of NFB in primary OS-
CCs,  or  in  non-tumorigenic  oral  keratinocytes 
(HOK-16B) leads to a significant increase in cytotoxi-
city and secretion of IFN- by the human NK cells [28, 
29]. However, it is only now that the underlying sig-
nificance  and  the  physiological  relevance  of  NFB 
modulation in tumors or in primary cells responsible 
for the alteration of NK cell cytotoxic function is being 
clarified. Indeed, targeted inhibition of NFB function 
in both the intestinal epithelial cells and the myeloid 
cells was previously shown to result in a significant 
decrease  in  the  size  and  the  numbers  of  the  tumor 
cells [30].  
In  this  paper  we  review  the  previous  studies 
from our laboratory and those of the others regarding 
the  factors  and  mechanisms  involved  in  immuno-
suppression observed in cancer, and furthermore we 
discuss the emerging view from our laboratory which 
indicates that the stage of maturation and differentia- Journal of Cancer 2011, 2 
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tion of healthy untransformed stem cells as well as 
transformed tumorigenic cancer stem cells is predic-
tive of their sensitivity to NK cell lysis. In this regard 
we  have  previously  demonstrated  that  OSCSCs, 
which  are  stem-like  oral  tumors,  are  significantly 
more  susceptible  to  NK  cell  mediated  cytotoxicity; 
whereas,  their  differentiated  counterpart  OSCCs  is 
significantly more resistant  [25]. In addition,  hESCs 
and iPSCs as well as a number of other healthy nor-
mal  stem  cells  such  as  hMSCs  and  hDPSCs  were 
found to be significantly more susceptible to NK cell 
mediated cytotoxicity than their differentiated coun-
terparts [25]. Based on these results, we propose that 
NK cells play a significant role in differentiation of the 
cells  by  providing  critical  signals  via  secreted  cyto-
kines as well as direct cell-cell contact. To be condi-
tioned to drive differentiation, NK cells may have to 
first receive signals either from healthy stem cells or 
those which have disturbed or defective capabilities to 
differentiate. In addition, NK cells by targeting other 
immune inflammatory cells or fibroblasts in the tumor 
microenvironment  may  become  conditioned  to  lose 
cytotoxicity and gain cytokine producing phenotype 
before they can aid in differentiation of oral squamous 
cancer stem cells. These alterations in NK cell effector 
function will ultimately aid in driving differentiation 
of a population of surviving healthy as well as trans-
formed stem cells. In cancer patients since the major-
ity of NK cells have lost cytotoxic activity, they may 
eventually contribute rather than halt the progression 
of  cancer  by  not  only  driving  the  differentiation  of 
tumor  cells  but  more  importantly,  by  allowing  the 
growth and expansion of the pool of cancer stem cells. 
Immunosurveillance in the Prevention of 
Cancer 
The theory of immunosurveillance was initially 
set forth by Burnet [31] to indicate that the key thy-
mus dependent effectors were responsible for clear-
ance of tumors [32, 33]. However, since then the con-
cept  of  immunosurveillance  has  been  expanded  to 
include immunoediting as an important mechanism 
for  the  development  of  cancer  [34];  [35].  It  was 
suggested  that  cancer  immunoediting  comprises  of 
three  phases:  elimination,  equilibrium  and  escape 
[35].  Elimination  represents  the  classical  concept  of 
immunosurveillance.  However,  during  equilibrium 
and  escape  the  interaction  and  cross  signaling  be-
tween  the  immune  effectors,  the  tumor  cells,  and 
perhaps the effectors of the connective tissue in the 
tumor microenvironment may result in the generation 
of tumors which are capable of gradual inactivation 
and  death  of  the  immune  effector  cells.  The  final 
stages  of  cancer  development  may  result  in  the  in-
duction of less immunogenic tumors in the presence 
of fewer immune effectors capable of lysing the tu-
mors. Thus, pressures exerted by the tumor cells and 
immune effectors may eventually shape the microen-
vironment for the growth, expansion and invasion of 
tumors. Similarly, some elements of such interactions 
could also be observed during the interaction of NK 
cells with healthy non-transformed human stem cells 
in which case the three phases of interaction may in-
clude  elimination  which  marks  the  decrease  in  the 
numbers of stem cells due to the selection of stem cells 
by  the  NK  cells,  induction  of  tolerance  or  anergy 
which  denotes  the  conditioning  of  NK  cells  by  the 
stem cells and/or by the other effectors of microen-
vironment  to  lose  cytotoxicity  and  support  matura-
tion and differentiation of stem cells, and finally the 
resolution  phase  which  denotes  the  elimination  of 
anergized  NK  cells  and  differentiation  of  selected 
stem cells. Similarities and differences between these 
phases in cancer and during stem cell maturation will 
be discussed below. 
Immune Responses in Cancer 
Although limited success in the immunotherapy 
with cytokines or adaptively transferred effector cells 
in metastatic melanomas or renal cell carcinomas have 
previously been observed, Immunotherapy has been 
found to be ineffective in the treatment of many other 
cancers  [36-38],  [39].  The  reasons  for  the  failure  of 
known immunotherapeutic modalities in many can-
cers including head and neck cancers are poorly un-
derstood. It has been hypothesized that a widespread 
paralysis of cytotoxic effectors residing inside the in-
flammatory infiltrate of advanced cancer patients is 
the main reason for poor prognosis [40, 41]. Further-
more, freshly isolated tumor infiltrating lymphocytes 
are not cytotoxic to autologous tumor cells and show 
a  significantly  reduced  clonogenicity  [14-16,  42]. 
Functional paralysis of cytotoxic cells have also been 
reported in a variety of cancers, notably breast [9, 10, 
43,  44],  renal  [7],  and  colon  [8].  More  importantly, 
depletion  of  cytotoxic  effectors  in  the  tumor  milieu 
has  an  unfavorable  outcome  for  survival  in  cancer 
patients  [43,  45-47].  Indeed,  a  significantly  shorter 
survival rate is reported for colorectal carcinoma pa-
tients with little or moderate NK infiltration as com-
pared to those with extensive infiltration [48]. A five 
year  survival  advantage  was  also  seen  with  higher 
CD3  positive  tumor  infiltrating  T  cells  than  with 
lower T cell count in the carcinoma of uterine cervix 
[47].  Regressing  tumor  grafts  of  oral  origin  contain 
significantly larger numbers of functional NK and T 
cells than those associated with the primary tumors  Journal of Cancer 2011, 2 
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[49], while patients with metastasis of head and neck 
cancers have low NK and T cell activity [50].  
Defects in NK, T and DCs have been reported in 
oral cancer patients. Signaling abnormalities, sponta-
neous  apoptosis  and  reduced  proliferation  of  circu-
lating  T  cells,  DCs  and  TILs  have  been  reported  in 
patients with oral cancers [51, 52].  
Mechanisms of Immunosuppression by Tumor 
Cells  
Many mechanisms have been proposed for the 
functional inactivation of tumor associated lympho-
cytes [7-11] (Table I). Soluble products derived from 
renal cell carcinoma inhibit proliferative capacity of T 
cells infiltrating human tumors due to a downregula-
tion of Janus kinase 3 (Jak 3), p56 (lck), p59 (fyn) and 
zap 70 [7]. Expression of Fas ligand by many human 
tumor cells including oral tumors has been hypothe-
sized to be a major cause of lymphocyte depletion in 
the tumor microenvironment [11]. In mice, tumor in-
duced immunosuppression has been associated with 
a decreased expression of the zeta-chain of the T cell 
receptor and the loss of mRNA for granzyme B [8]. 
Indeed,  as  observed  in  mice,  the  frequency  of 
TCR-zeta positive and granzyme positive T cells are 
decreased in advanced stage head and neck carcino-
mas  in  humans,  and  the  restoration  of  expression 
during in vitro stimulation suggests the presence of 
tumor derived suppressive factors [8]. However, cau-
tion should be exercised in extending the results from 
mice cancer model to human disease model in terms 
of NK cell function due to an array of species specific 
differences. We have found that freshly isolated NK 
cells from humans have significant cytotoxic activity 
against sensitive tumors or healthy stem cells imme-
diately  after  purification  [53],  however,  freshly  iso-
lated NK cells from mice not only lacked any signifi-
cant  cytotoxicity  against  sensitive  tumors  such  as 
YAC-1, immediately after purification or after an ex-
tended period of incubation, but also they required a 
much  longer  period  of  activation  with  IL-2  for  the 
acquisition of significant cytotoxicity [54]. In addition, 
we have found that a greater amount of IL-2 was re-
quired  for  the  activation  of  NK  cells  from  mice  to 
mediate  cytotoxicity  whereas  in  humans  not  only 
much lower amounts of IL-2 could trigger activation 
of cytotoxicity but also IL-2 treatment in humans re-
quired  a  very  short  period  of  time  (hours  and  not 
days) for significant increase in cytotoxicity [53, 54]. 
These differences could be due to the strain of mice 
used or the source from which purified NK cells were 
isolated in mice and humans; i.e. spleen vs. peripheral 
blood or could be due to the inherent differences be-
tween human and mice NK cell function. The latter 
may be likely since species specific differences for the 
use of key surface receptors for the NK cell function 
have previously been reported by others [55]. Indeed, 
it was stated in a previous report that “The extraor-
dinary and unanticipated  divergence of human NK 
cell  receptors  and  MHC  class  I  ligands  from  their 
mouse counterparts can in part explain the difficulties 
experienced in finding informative mouse models of 
human diseases” Thus, mouse model “has been un-
impressive in producing informative and translatable 
models of human diseases” [55]. It is, however, a very 
convenient model which can be genetically manipu-
lated, and as such can give a wealth of knowledge if 
used in parallel with the human disease model con-
firming the observations obtained in human disease 
and not vice versa. It is outside the scope of this re-
view  to  provide  a  complete  description  of  species 
specific differences of NK cell receptors. Interestingly, 
most  studies  reported  for  tumor  mediated  NK  cell 
immunosuppression was conducted using human NK 
cells.  Therefore,  decreased  CD16  and  its  associated 
zeta chains were observed in tumor infiltrating NK 
cells of patients with cancer [22] (Table I), thus, cor-
relating in phenotype with our in vitro inactivated NK 
cells  by  sensitive  tumors  [20,  56].  Overall  both  se-
creted factors and direct cell-cell contact during the 
interaction of immune effectors with the tumor cells in 
patients  were  shown  to  be  responsible  for  the  sup-
pression of immune effector function. 
Immunosuppression mediated by secreted 
factors  
Many secreted factors such as PGE2, Interleukin 
(IL)-6,  Vascular  Endothelial  Growth  Factor  (VEGF) 
and Granulocyte Monocyte Colony Stimulating Fac-
tor (GM-CSF) are known to induce Immunosuppres-
sion  in  the  tumor  microenvironment.  Immunosup-
pression linked to enhanced PGE2 synthesis has been 
documented  in  many  human  cancers  [57].  Freshly 
excised human head and neck cancers demonstrated 
elevated levels of PGE2, transforming growth factor- 
1 (TGF1) and interleukin-10 (IL-10) secretion which 
are  known  to  upregulate  the  expression  of  Killer 
Immunoglobulin-like Receptors (KIRs) on the surface 
of NK, T and DCs and block immune effector function 
[58]. Furthermore, metastatic head and neck cancers 
released higher levels of above-mentioned inhibitory 
factors and lower levels of immune activating factors 
IFN-and IL-2 than did their corresponding primary 
tumors [58]. PGE2 overproduction in tumor microen-
vironment  was  also  shown  to  lead  to  dendritic  cell 
(DC) abnormalities [59].  
 IL-6,  another  immunosuppressive  factor  is  se-
creted  constitutively  by  oral  squamous  carcinomas  Journal of Cancer 2011, 2 
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[60], and is found to be elevated in oral cancer patients 
[61]. IL-6 is known to interfere with IFN- signaling by 
the induction of Th2 differentiation [62]. In support of 
a role for IL-6 in mediating immune evasion of tumor 
cells, Menetrier-Caux et al showed that conditioned 
medium from human renal cell carcinoma cell lines 
blocked  the  differentiation  of  CD34+  bone  marrow 
cells  into  immature  DCs,  and  this  inhibitory  effect 
could be blocked with antibodies against IL-6 [63].  
Other  factors  which  have  been  implicated  in 
immunosuppression in cancers are angiogenic factors 
such as VEGF [64] and cytokines such as G-CSF and 
GM-CSF. The finding that neutralizing antibodies to 
VEGF or GM-CSF could partially reverse the inhibi-
tory effects of tumor cell supernatant on DC matura-
tion  demonstrated  that  these  factors  could  interfere 
with DC differentiation and function [64]. Increased 
numbers of immature DCs were found in the periph-
eral blood of cancer patients with elevated levels of 
circulating VEGF [64].  
Immunosuppression Mediated by Direct 
Cell-Cell Contact.  
Contact-dependent  immune  suppression  can 
occur by engagement of  MHC class I  molecules on 
CD8+CD28-  suppressor  cells  with  immunoglobu-
lin-like transcript (ILT2 and ILT4) inhibitory receptors 
on DCs. Blocking of both MHC Class I and ILTs by 
specific  antibodies  can  reverse  immunosuppression 
[65].  Similarly  binding  of  c-type  lectin  receptors  or 
Killer Immunoglobulin-like Receptors (KIRs) to MHC 
Class I ligands inhibit NK cell function (Wagtmann et 
al, 1995; D’Andrea et al, 1995; Lazetic et al, 1996; Car-
retero et al, 1997;Brooks et al, 1997). In addition, the 
expression of co-stimulatory molecules, such as B7H1 
on tumor cells and inhibitory DCs and T cells can in-
hibit T cell activation and proliferation (Cuiel, et al., 
2003). 
Immunosuppressive effectors in tumor mi-
croenvironment  
The  tumor  microenvironment  consists  of  a 
number of heterogeneous cell populations with ability 
to  suppress  and  limit  the  function  and  survival  of 
cytotoxic immune effectors. Patients with cancer often 
have  higher  numbers  of  immature  CD14+HLADR- 
monocytes  [66,  67].  Tumor  associated  Macrophages 
(TAMs)  were  previously  shown  to  significantly  in-
fluence and limit immune activation in the tumor mi-
croenvironment [68, 69]. In addition, Myeloid Derived 
Suppressor Cells (MDSCs) which are comprised of a 
number of distinct cell populations of myeloid origin 
and  whose  roles  in  immunosuppression  have  re-
ceived significant attention in recent years are major 
cells capable of suppressing the cytotoxic function of 
T  and  possibly  NK  cells  [67].  T  cell  dysfunction  is 
shown to be induced by MDSCs by the secretion of 
IL-10, TGF-, reactive oxygen species (ROS), arginase 
and Nitric Oxide synthase (NOS). T regulatory (Treg) 
and DC regulatory (DCreg) cells were also recently 
shown to have significant immunosuppressive roles 
in the tumor microenvironment [67]. Perhaps one of 
the  most  interesting  observations  regarding  the  im-
munosuppressive  effectors  is  the  identification  of 
Cancer  Associated  Fibroblasts  (CAFs)  and  Mesen-
chymal  Stem  Cells  (MSCs)  as  two  potential  tumor 
promoters.  Fibroblasts  from  tumor  tissues  demon-
strate an activated phenotype and have the ability to 
secrete  many  immunosuppressive  factors  such  as 
TGF- and VEGF [70]. We have also found that fibro-
blasts, as well as MSCs and CD14+HLA-DR- mono-
cytes irrespective of their surface expression of CD16 
are significantly more susceptible to NK cell mediated 
cytotoxicity [71], therefore, these cells may condition 
NK  cells  to  become  anergic  (please  see  below).  In-
deed,  in  oral  epithelial  tumors  the  majority  of  re-
cruited  immune  effectors  are  usually  found  in  the 
connective tissue area where through cell-cell interac-
tion with the immunosuppressive cells such as fibro-
blasts, monocytes-macrophages and to a lesser extent 
T and B cells [71] can condition NK cells to lose cyto-
toxicity  and  gain  in  cytokine  secretion  capabilities, 
resulting in differentiation and resistance of oral epi-
thelial tumors (please see below).  
Role of NFB in tumor resistance 
Although each one of the secreted factors indi-
vidually can be responsible in part for the resistance 
of tumors, previous data obtained from different la-
boratories [29, 72] indicated that targeting transcrip-
tion factors may be more effective in decreasing re-
sistance of tumors to immune mediated cytotoxicity. 
Many  tumor  cells  exhibit  constitutively  elevated 
NFB  activity  [23].  Human  leukemias  and  lympho-
mas as well as human solid tumors exhibit constitu-
tively activated NFB in the nucleus [23].  
We  have  shown  previously  that  NFB  nuclear 
function  in  a  primary  Oral  tumor  OSCCs  and  in  a 
non-tumorigenic oral cells (HOK-16B) as well as in an 
established tumor line, HEp-2 cells known to be Hela 
contaminant  [29,  73-75],  modulates  and  shapes  the 
function of interacting immune effectors [28, 29]. It is 
believed that HEp-2 cells are Hela contaminants since 
cells of these lines are shown to contain Hela marker 
chromosomes  (ATCC).  Since  knock  down  of  NFB 
was  shown  to  increase  the  function  of  immune  in-
flammatory cells in diverse cell types (please see be-
low)  it  is  not  surprising  to  find  similar  patterns  of  Journal of Cancer 2011, 2 
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immune activation in both oral and non-oral derived 
cell lines, even in those which have been derived from 
contaminants such as Hela cells. In addition, since the 
majority  if  not  all  cells  increase  NFB  during  their 
activation and differentiation, a knock down of NFB 
is likely to revert the cells, irrespective of their cellular 
origin, to their less differentiated phenotypes result-
ing in the potential activation of the immune effectors 
in order to aid in their differentiation [25]. Therefore, 
inhibition of NFB in oral tumors resulted in a signif-
icant activation of human NK cell cytotoxic function 
and increased IFN- secretion [25]. Similarly, inhibi-
tion  of  NFB  by  Sulindac  increased  the  functional 
activation of NK and enhanced anti-tumor cytotoxic 
activity [28, 29]. Inverse modulation of IFN- and IL-6 
cytokine secretion was seen in co-cultures of NK cells 
with NFB knock down OSCCs and HEp2 cells indi-
cating  that  blocking  NFB  in  these  cells  serves  to 
switch the balance from Th2 type responses to more of 
a Th1 type response [25, 28].  
NFB inhibition in mice and humans activate 
immune inflammatory functions 
In agreement with our studies, targeted deletion 
of  Iκκ-β  in  epidermis  of  mice  has  previously  been 
shown  in  one  study  to  lead  to  inflammatory  skin 
manifestations  similar  to  that  seen  in  patients  with 
Incontinentia  Pigmenti  (IP)  [76].  Elevated  levels  of 
cytokines  and  chemokines  have  also  been  demon-
strated in the epidermis of patients and animals with 
I  and  I  deletions  [76,  77].  Blocking  of  NFB 
function by deleting I- in intestinal epithelial cells 
also  dramatically  decreased  the  rate  of  tumor  for-
mation  without  affecting  the  size  of  the  tumors  in 
colitis-associated  cancer  model  [78,  79].  Moreover, 
deleting  I-  in  myeloid  cells  in  the  same  model 
system resulted in the decrease in tumor size. These 
studies underscore the significance of the cross talk 
between  different  subsets  of  immune  effectors  with 
the epithelial cells in induction and progression of the 
intestinal tumors.  
Mice  with  a  keratinocyte-specific  deletion  of 
I  demonstrated  decreased  proliferation  of  epi-
dermal  cells  and  developed  TNF-  dependent  in-
flammatory  skin  disease  [76].  In  contrast,  in  other 
studies in which NFB function was blocked in der-
mal  keratinocytes  by  a  mutant  IB-  an  increased 
proliferation  and  hyperplasia  [80]  and  eventual  de-
velopment of cutaneous squamous cell carcinomas of 
skin were seen if mice were allowed to survive and 
reach adulthood [81, 82]. It is of interest to note that in 
these  studies  with  diverse  functional  outcomes  in 
keratinocytes, blocking TNF- function resulted in the 
prevention of both the neoplastic transformation and 
the inflammatory skin disease [76, 82] . Thus, it ap-
pears that TNF- is the primary factor mediating the 
pathological processes in both of these studies. Ele-
vated  numbers  of  immune  inflammatory  cells  re-
cruited to the site of epidemis are likely responsible 
for the increased secretion of TNF-. Indeed, we have 
demonstrated  that  synergistic  induction  of  TNF- 
could be observed when NFB knock down oral tu-
mors were cultured with either PBMCs or NK cells 
[28].  
NK cells lyse cancer stem cells, as well as 
hESCs, hiPSCs, hMSCs and hDPSCs but not their 
differentiated counterparts 
 Increased NK cell cytotoxicity and augmented 
secretion of IFN- were observed when NK cells were 
co-incubated  with  OSCSCs  which  released  signifi-
cantly  lower  levels  of  GM-CSF,  IL-6  and  IL-8  and 
demonstrated decreased expression of phospho-Stat3, 
B7H1 and EGFR, and much lower constitutive NFB 
activity when compared to differentiated OSCCs [25]. 
More  importantly,  OSCSCs  expressed  CD133  and 
CD44bright  oral  stem  cell  markers  [25].  Increase  in 
IFN- secretion was correlated with a decrease in se-
cretion of IL-6 in co-cultures of NK cells with OSCSCs 
as  compared  to  those  co-cultured  with  OSCCs. 
Therefore, from these results a specific profile for dif-
ferentiated NK resistant oral tumors emerged which 
demonstrated increased GM-CSF, IL-6 and IL-8 secre-
tion in the context of decreased IFN- secretion during 
their  interaction  with  the  NK  cells.  In  contrast, 
co-cultures of cancer stem cells with NK cells demon-
strated  increased  IFN-  in  the  context  of  lower 
GM-CSF, IL-6 and IL-8 secretion [25, 71]. In addition, 
three brain tumor stem cells which were previously 
characterized  [83-85]  were  found  to  be  significantly 
more  susceptible  to  NK  cell  mediated  cytotoxicity 
when  compared  to  their  differentiated  counterparts 
which were significantly more resistant (manuscript 
submitted). Since OSCSCs and brain stem cells were 
significantly  more  susceptible  to  NK  cell  mediated 
cytotoxicity  we  reasoned  that  healthy, 
non-transformed primary stem cells may also be sus-
ceptible to NK cell mediated cytotoxicity. We demon-
strated previously that NK cells lysed hMSCs, hDP-
SCs  and  hESCs  significantly.  All  different  types  of 
stem cells became resistant to NK cell mediated cyto-
toxicity  once  they  were  differentiated  [25].  In  addi-
tion, higher sensitivity of hiPSCs to NK cell mediated 
lysis was also observed when compared to parental 
line from which they were derived. Increased lysis of 
cancer  stem  cells  or  non-transformed  healthy  stem 
cells may be attributed to the use of allogeneic NK  Journal of Cancer 2011, 2 
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cells, however, our previous work using autologous 
NK  cells  exhibited  similar  levels  of  cytotoxicity 
against DPSCs when compared to lysis by allogeneic 
NK cells [71]. Taken together these results indicated 
that  undifferentiated  cells  were  targets  of  both  al-
logeneic and autologous NK cells. Thus, the stage of 
differentiation of the cells is predictive of their sus-
ceptibility to NK cell mediated cytotoxicity.  
Blocking NFB reverts the cells to more of an 
undifferentiated phenotype and increases NK 
cell mediated cytotoxicity against oral tumors.  
 Since the degree of differentiation in the cells is 
predictive  of  their  sensitivity  to  NK  cell  mediated 
cytotoxicity, we reasoned that blocking NFB in the 
cells may de-differentiate and consequently revert the 
cells to more of undifferentiated phenotype, resulting 
in their increased susceptibility to NK cell mediated 
cytotoxicity.  Indeed,  blocking  NFB  in  oral  tumors 
was also found to increase CD44 surface receptor ex-
pression, which is one of the hallmarks of stem cells 
(manuscript in prep). In addition, the profiles of cy-
tokines  secreted  in  the  co-cultures  of  NK  cells  or 
PBMCs  with  NFB  knock  down  tumors  resembled 
those secreted in the co-cultures of NK cells with the 
stem  cells  [25,  28,  71].  Since  tumorigenic  and 
non-tumorigenic  human  oral  keratinocytes  acquire 
sensitivity to NK cell mediated lysis when NFB is 
inhibited, it is likely that this phenomenon is not spe-
cific to cancer or oral keratinocytes, and it may occur 
in other healthy non-transformed cell types. Indeed, 
when human primary monocytes were differentiated 
to dendritic cells they too became more resistant to 
NK cell mediated cytotoxicity [25]. Moreover, knock 
down of COX2 in primary mouse monocytes [25], or 
in mouse embryonic fibroblasts (manuscript in prep), 
resulted in the reversion or de-differentiation of the 
monocytes and fibroblasts respectively, and the acti-
vation of NK cell cytotoxicity. Indeed, it is likely that 
any  disturbance  in  cellular  differentiation  may  pre-
dispose  the  cells  to  NK  cell  mediated  cytotoxicity. 
Since STAT3 is an important factor increased during 
differentiation, blocking STAT3 is also critical in the 
activation of immune effectors [72]. In support of a 
critical  role  of  STAT3  in  immune  evasion  of  tumor 
cells in humans, we and others have recently shown 
that glioblastoma multiforme (GBM) tumors display 
constitutive  activation  of  STAT3  (Cacalano  and 
Jewett,  unpublished  observation)  [86],  and  poorly 
induce activating cytokines and tumor-specific cyto-
toxicity in human peripheral blood mononuclear cells 
(PBMCs) and NK cells. Ectopic expression of domi-
nant-negative STAT3 in the GBM cells increased lysis 
of  the  tumor  cells  by  the  immune  effectors  and  in-
duced production of IFN- by the interacting immune 
effectors (manuscript in prep).  
Since NFB is shown to regulate IL-6 secretion in 
OSCCs, HOK-16B and HEp2 cells and secreted IL-6 in 
tumors is known to activate STAT3 expression and 
function, increase in NFB nuclear function could in 
turn induce STAT3 activation and result in a signifi-
cant resistance of tumors to NK cell mediated cyto-
toxicity. Therefore, targeted knock down of STAT3 or 
signaling  pathways  upstream  of  STAT3,  such  as 
NFB, may de-differentiate the cells and predispose 
the cells to NK cell mediated cytotoxicity.  
Induction of split anergy in NK cells after their 
co-culture with sensitive but not resistant 
tumors and after the triggering of CD16 on IL-2 
treated NK cells 
We  have  previously  shown  that  K562,  an  NK 
sensitive  tumor,  causes  loss  of  NK  cell  cytotoxicity 
and induces cell death in a small subset of NK cells 
[20, 21]. On the other hand NK resistant tumors such 
as RAJI cells induce much less anergy or loss of NK 
cell cytotoxicity [20, 21]. Furthermore, following NK 
cell cultures with sensitive tumor-target cells but not 
resistant tumors, the target binding NK cells undergo 
phenotypic and functional changes. Target cell inac-
tivated  NK  cells  express  CD16-CD56dim/-  CD69+ 
phenotype [20, 21]. This phenotype has also been ob-
served  in  several  disease  manifestations  including 
HIV  infection  [87].  Significant  downmodulation  of 
CD16 receptor expression and decreased NK cell cy-
totoxic function were also seen in several cancer pa-
tients including those of the oral and ovarian cancer 
patients  [88,  89].  In  addition,  down-regulation  of 
CD16 surface receptors on NK cells was also observed 
when NK cells were treated with CA125 isolated from 
ovarian tumor cells [90]. The decrease in CD16 surface 
receptors  was  accompanied  by  a  major  decrease  in 
NK cell killing activity against K562 tumor cells [90]. 
These  observations  suggested  that  CD16  receptors 
may play an important role in target cell induced loss 
of NK cell cytotoxicity. Indeed, CD16:Ig fusion pro-
teins are shown to bind to a variety of tumor-target 
cells  indicating  the  existence  of  specific  ligands  for 
CD16 receptors on tumor cells [91]. Furthermore, we 
have previously shown that the triggering of CD16 on 
untreated or IL-2 treated NK cells was found to result 
in downmodulation of CD16 receptors and in a great 
loss of cytotoxicity in NK cells. In addition, a subset of 
NK cells was programmed to undergo apoptosis [20, 
21, 56, 92]. Cell death of NK cells was shown to be 
regulated, in part, by endogenously secreted TNF- 
from  the  NK  cells [56].  Previous  studies  by  other 
groups have also shown that IL-2 activated NK cells  Journal of Cancer 2011, 2 
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undergo  cell  death  following  cross-linking  of  the 
CD16 receptor [93, 94]. Thus, we have coined the term 
“split anergy” for the responses observed by NK cells 
after  their  interaction  with  sensitive  target  cells  or 
after the triggering of CD16 receptors by the antibody 
in combination with IL-2 treatment [20, 21, 53, 56, 95]. 
Indeed,  three  subpopulations  of  NK  cells;  namely 
Free, Binder and Killer NK cells with varying degrees 
of  loss  of  cytotoxicity  were  identified  after  the  for-
mation  of  conjugates  with  K562  targets  [92,  96-99]. 
Free cells which did not bind or form conjugates with 
target  cells  were  inactivated  less,  or  exhibited  the 
most  cytotoxicity,  whereas  both  Binder  and  Killer 
subsets  exhibited  significant  loss  of  cytotoxicity.  In 
contrast, Binder and Killer subsets but not Free NK 
subset  secreted  significant  levels  of  cytokines  and 
exhibited  CD16-CD56dim/-CD69+  phenotype  [92, 
96-99].  Treatment  of  NK  cells  with  IL-2  and  an-
ti-CD16mAb  also  induced  split  anergy  by  signifi-
cantly decreasing the NK  cell cytotoxicity while in-
creasing  the  cytokine  secretion  capabilities  of  NK 
cells.  Furthermore,  NK  cells  exhibited 
CD16-CD56dim/-CD69+  phenotype  after  treatment 
with the combination of IL-2 and anti-CD16mAb [53, 
56, 95, 100]. Loss of cytotoxicity in NK cells was sig-
nificantly  exacerbated  when  NK  cells  were  either 
treated  with  F(ab)’2  fragment  of  anti-CD16  mAb  or 
treated with a combination of MHC-Class I and an-
ti-CD16 mAb while the same treatments resulted in an 
increased  secretion  of  cytokines  [53,  100].  These  re-
sults suggested that receptor signaling in NK cells in 
the presence of IL-2 is likely to result in a decrease in 
NK cell cytotoxicity while increasing secretion of cy-
tokines  by  the  NK  cells.  Therefore,  three  distinct 
functional  outcomes  could  be  observed  in  NK  cells 
which  have  either  interacted  with  sensitive  tu-
mor-target cells or were treated with anti-CD16 mAb 
in the presence of IL-2 treatment to induce split an-
ergy,  namely;  1-Loss  of  cytotoxicity,  2-gain  in  the 
ability  to  secrete  cytokines  and  3-  death  in  a  small 
subset of NK cells.  
Split anergy in NK cells is induced by mono-
cytes and those depleted of CD16+ subsets of 
monocytes  
When MSCs or DPSCs were cultured with either 
viable or irradiated monocytes before they were ex-
posed to IL-2 treated NK cells a significant decrease in 
NK  cell  mediated  cytotoxicity  could  be  observed 
against MSCs or DPSCs. Interestingly, significant lysis 
of MSCs and DPSCs by untreated NK cells was also 
significantly and reproducibly blocked by the addi-
tion of monocytes [71]. To determine whether CD16- 
subset of monocytes were also able to inhibit the cy-
totoxic function of NK cells in a 3 way interaction with 
the stem cells we used both the unsorted, and those 
sorted to remove CD16+ subsets in a 3 way killing 
assay with the NK cells. Both the total populations of 
monocytes  and  CD16-  subsets  were  capable  of  in-
ducing inhibition of NK cell cytotoxicity against stem 
cells  [71].  We  then  determined  whether  decreased 
lysis of stem cells by NK cells was due to a competi-
tive lysis of monocytes by the NK cells. We confirmed 
that monocytes were also lysed by the NK cells sig-
nificantly.  Furthermore,  when  we  co-cultured  stem 
cells with monocytes and sorted to remove the mon-
ocytes from the stem cells before assessing the killing 
function of NK cells, we could still observe significant 
inhibition of NK cell mediated lysis, arguing against 
the  protection  of  stem  cell  lysis  by  NK  cells  being 
solely on the bases of competitive lysis of monocytes 
[71]. Therefore, even though lysis of monocytes by the 
NK cells may in part contribute to the prevention of 
NK cell lysis of stem cells, interaction of monocytes 
with  stem  cells  can  also  provide  resistance  of  stem 
cells against NK cell cytotoxicity. Decrease in NK cell 
lysis of MSCs and DPSCs by monocytes was paral-
leled  with  a  significant  induction  of  IFN-.  Indeed, 
when MSCs or DPSCs were cultured with IL-2 treated 
NK cells alone we could observe significant induction 
of IFN- secretion. However, the highest increase was 
seen when IL-2 treated NK cells were cultured with 
MSCs  or  DPSCs  in  the  presence  of  monocytes. 
Therefore, although decreased killing of stem cells by 
the  NK  cells  could  be  observed  in  the  presence  of 
monocytes, synergistic secretion of IFN- by the NK 
cells  in  the  presence  of  monocytes  and  stem  cells 
could be observed, indicating an inverse relationship 
between cytotoxicity and IFN- secretion (split aner-
gy).  This  was  similar  to  the  profiles  which  we  had 
seen when NK cells were treated with IL-2 and an-
ti-CD16 antibody in which significant decrease in cy-
totoxicity  of NK cells could be observed in parallel 
with increased secretion of IFN- (split anergy) [56].  
Tumor microenvironment may shape the 
function and phenotype of the NK cells 
The above observations prompted us to specu-
late regarding the significance of interaction of mon-
ocytes with NK cells and stem cells. It is plausible that 
monocytes may serve as shields against NK cell lysis 
of stem cells. Similar to anti-CD16 antibody mediated 
effect  on  IL-2  treated  NK  cells,  monocytes  too  can 
shield stem cells from killing by the NK cells by in-
creasing the total IFN- release by the NK cells while 
decreasing  the  cytotoxic  function  of  NK  cells  (split 
anergy), resulting in an increased protection and dif-
ferentiation of stem cells. Indeed, monocytes also in- Journal of Cancer 2011, 2 
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creased  TNF-  IL-6  and  VEGF  secretion  in  the 
co-cultures of stem cells with NK cells which could 
augment  NFB  and  increase  differentiation  of  stem 
cells.  The  shielding  effect  of  monocytes  could  be  a 
more generalized function of other effectors since NK 
cells can also target fibroblasts and to a much lesser 
extent  the  T  and  B  cells  [71].  Whether  MDSCs  or 
PMNs could also be targeted by the NK cells awaits 
future  investigation.  This  may  have  significant  im-
plications regarding the role of NK cells in not only 
limiting  inflammation,  but  also  the  significance  of 
other immune effectors in shielding and limiting the 
cytotoxic  function  of  NK  cells  against  cancer  or 
healthy stem cells in order to raise maximally the se-
cretion of key cytokines for speedy and optimal dif-
ferentiation of stem cells during inflammation. This is 
precisely what is observed in cancer patients in whom 
global decrease in NK, cytotoxic T cells and  mono-
cytes have all been reported [12].  
Potential role of anergized NK cells in differ-
entiation and regeneration of tissues 
 Even though conditioning of NK cells to support 
differentiation of cells is discussed in the context of 
tumors, induction of split anergy in NK cells, we be-
lieve,  is  an  important  conditioning  step  responsible 
for the repair of tissues during pathological processes 
irrespective of the type of pathology. In tumors since 
the generation and maintenance of cancer stem cells is 
higher, the majority if not all of the NK cells may be 
conditioned to support differentiation and repair of 
the tissues and as such the phenotype of NK cells in 
tumor microenvironment as well as in the peripheral 
blood may resemble that of the anergic NK cells, i.e., 
decreased  NK  cell  cytotoxicity,  acquisition  of 
CD16-/dimCD56-/dimCD69+  phenotype  and  aug-
mented ability to secrete inflammatory cytokines (Fig. 
2). Of course, the degree of the loss of NK cell cyto-
toxicity may be directly proportional to the load of 
cancer stem cells. Therefore, our results suggest two 
very important functions for the NK cells. One func-
tion is to limit the number of stem cells by selecting 
those with a greater potential for differentiation for 
the repair of the tissues and second to support dif-
ferentiation of the stem cells and subsequent regener-
ation of the tissues. To achieve these tasks NK cells 
have  to  acquire  two  different  phenotypes  and  be 
conditioned to carry out both functions successfully. 
CD16+CD56+/dimCD69- subsets of NK cells are cy-
totoxic  and  will  mediate  cytotoxicity  depending  on 
which sensitive targets they encounter first. In respect 
to the oral squamous cell carcinomas since the major-
ity of immune effectors can be found at the connective 
tissue  area  the  chances  are  that  they  may  first  en-
counter  and  interact  with  either  the  other  immune 
effectors or the effectors of connective tissue such as 
fibroblasts. However, there is also the possibility that 
NK cells may first encounter the stem cells at the base 
of the epithelial layer, in which case by eliminating 
their bound stem cells, they too can become anergized 
(Fig. 1). Surprisingly, allogeneic CTLs were also found 
to  target  Glioblastoma  stem-like  cells  and  not  their 
differentiated counterparts (Veronique Quillien, per-
sonal  communication).  By  eliminating  a  subset  of 
stem cells or after their interaction with other immune 
inflammatory  cells  or  effectors  of  connective  tissue 
NK cells could then be in a position to support dif-
ferentiation of selected population of stem cells since 
they will be conditioned to lose cytotoxicity, induce 
cytokine  and  growth  factor  secretion  and  gain  the 
CD16-/dimCD56dimCD69+ phenotype (Fig. 2). It is 
interesting  to  note  that  all  of  the  immune  effectors 
isolated from oral gingival tissues of healthy as well 
as diseased gingivae have CD69+ phenotype, with the 
exception that the numbers of immune effectors are 
much less in the healthy oral gingival tissues when 
compared  to  diseased  tissues  (manuscript  in  prep). 
Therefore,  our  results  suggest  two  very  important 
functions for the NK cells. One function is to kill and 
the other function is to be conditioned to support dif-
ferentiation for the repair and regeneration of the tis-
sues. 
In  vivo  physiological  relevance  of  above- 
mentioned observations could be seen in a subpopu-
lation  of  NK  cells  in  peripheral  blood,  uterine  and 
liver NK cells which express low or no CD16 recep-
tors, have decreased capacity to mediate cytotoxicity 
and is capable of secreting significant amounts of cy-
tokines  [101, 102]. In addition, 70%  of NK cells  be-
come  CD16  dim  or  negative  immediately  after  al-
logeneic or autologous bone marrow transplantation 
[101]. Since NK cells lose their cytotoxic function and 
gain  in  cytokine  secretion  phenotype  and  down 
modulate CD16 receptors after their interaction with 
tumor cells or the stem cells [20, 56], it is tempting to 
speculate that in vivo identified CD16- NK cells and 
in vitro tumor induced CD16- NK cells have similar 
developmental  pathways  since  they  have  similar  if 
not identical functional properties.  Journal of Cancer 2011, 2 
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Fig. 1 Schematic representation of hypothetical model of oral cancer stem cell differentiation by NK cells. Based 
on our previous results [25, 71], OSCSCs initially express the phenotype listed in the figure (left panel). Upon con-
ditioning of NK cells to lose cytotoxicity and gain in cytokine secretion and expressing CD16-CD56dim/-CD69+ surface 
phenotype (middle panel), either by immune inflammatory cells such as monocytes (for more detail see figure 2) or 
stem cells, the phenotype of stem cells is modified as shown in the right panel, and they become differentiated to 
support tissue regeneration.  
 
Fig. 2 Immune inflammatory cells are mainly concentrated in the connective tissue area right beneath the ep-
ithelial layer of OSCC. The slides from OSCC were prepared and stained with H&E (left panel). At the right panel the 
hypothetical model of NK cell conditioning in the tumor microenvironment is over imposed on the actual slide shown  Journal of Cancer 2011, 2 
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on the left panel. On the left panel significant infiltration of immune effectors right beneath the epithelial layer can 
be seen in the connective tissue area where the immune inflammatory cells are likely to condition NK cells to lose 
cytotoxicity and to support differentiation of epithelial cells. At the right panel two hypothetical mechanisms for 
conditioning of NK cells to support differentiation of stem cells are shown. In one scenario, NK cells, may first en-
counter and interact with either the other immune effectors as listed in the figure or the effectors of connective 
tissue such as fibroblasts to undergo split anergy (NKSA). In a second scenario, NK cells may also directly encounter the 
stem cells at the base of the epithelial layer, in which case by eliminating their bound stem cells, they too can 
become anergized to support differentiation of other stem cells. Both mechanisms may be operational in the tumor 
microenvironment. 
 
The ultimate proof of concept in support of this 
model  was recently  obtained in our laboratory. We 
observed  that  anergized  NK  cells  directly  were  re-
sponsible  for  the  increased  differentiation  and  re-
sistance of a number of different stem cells including 
cancer  stem  cells  against  cytotoxic  effectors  (manu-
script submitted). In addition, we now have evidence 
which supports the notion that the induction of an-
ergy in NK cells is an active process which is induced 
by the triggering of CD16 receptor on the NK cells and 
is not due to degranulation and exhaustion of cyto-
toxic granules (manuscript in prep).  
Our  work  collectively  suggests  that  anergized 
NK cells are as important as the non-anergized NK 
cells in their effector functions. NK cells are not only 
important for the removal and shaping of the size of 
the stem cells but also their differentiation, and the 
ultimate regeneration of the new tissues. The task of 
NK cells in this regard goes above and beyond their 
most  appreciated  function  of  being  the  effectors  of 
first  line  defense  against  viral  infection  and  malig-
nancies. They too can be  effectors of differentiation 
and tissue regeneration.  
Conclusion 
Recent  advances  in  our  understanding  of  an-
ti-tumor immune responses and cancer biology have 
revealed a complex dynamic interaction between the 
immune effectors and the tumor cells. Effectors of the 
immune system are known to shape the tumor cells 
(immunoediting)  and  to  select  for  cancers  with  re-
duced immunogenicity and enhanced capacity to ac-
tively  induce  immunosuppression.  However,  the 
same effector mechanisms are likely responsible for 
the selection of healthy stem cells with enhanced ca-
pacity to induce immunosuppression for the ultimate 
goal of the regeneration of damaged or disturbed tis-
sues and the resolution of inflammation. Much work 
has been done to identify strategies by which tumor 
cells evade the function of immune system. Altered 
expression of MHC molecules which block recogni-
tion and activation of T and NK cells are examples of 
mechanisms by which tumor cells evade the function 
of  immune  system.  In  addition,  tumor  cells  by  re-
leasing  immunosuppressive  factors  such  as  Fas, 
VEGF, IL-6, IL-10, TNF-, GM-CSF and IL-1, induce 
T and NK cell apoptosis, block lymphocyte homing 
and  activation,  and  dampen  macrophage  and  den-
dritic cell function. However, the same effector func-
tions are also important in tissue repair. Furthermore, 
progress has been made in identification of the up-
stream mechanisms which control the expression of 
immunosuppressive factors in tumor cells. Two key 
control  elements,  NFB  and  STAT3  were  identified 
and shown to coordinately regulate the production of 
multiple  tumor-derived  immunosuppressive  mole-
cules and play a pivotal role in tumor cell immune 
suppression.  The  potential  for  these  two  signaling 
modules to repress immune responses is underscored 
by  the  finding  that  the  pathways  interact  and  may 
even  amplify  each  other.  One  model  for 
NFB-STAT3-mediated immunosuppression suggests 
that NFB-induced IL-6 expression activates STAT3 in 
tumor cells and modulates the production of inhibi-
tory cytokines and chemokines resulting in decreased 
T cell infiltration and activation. However, the same 
mechanisms  are  likely  to  be  important  for  normal 
tissue regeneration and induction of resistance to NK 
and T cell mediated cytotoxicity.  
Based on the accumulated work presented in this 
review we suggest that NK cells may have two sig-
nificant functions; one that relates to the removal of 
stem cells that are either defective or disturbed or in 
general more in numbers than are needed for the re-
generation  of  damaged  tissue.  Therefore,  they  may 
select stem cells that are competent and are able to 
achieve the highest ability to regenerate tissues. Al-
ternatively, or in addition, NK cells may lyse other 
effectors in the connective tissue area in order to not 
only decrease inflammation but also to be conditioned 
to promote tissue regeneration. The second important 
task for NK cells is therefore, to support differentia-
tion  and  promote  tissue  regeneration  after  altering 
their  phenotype  to  cytokine  secreting  cells  (Fig.  2). 
This process will not only remove cells that are dam-
aged and have flaws in the differentiation process, but 
also it will ensure the regeneration of tissues and the 
resolution of inflammation. Thus, any disturbance in  Journal of Cancer 2011, 2 
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the NK cell function may result in a chronic inflam-
matory process, causing continual tissue damage and 
recruitment of immune effectors to aid in tissue re-
generation.  
The inability of patient NK cells to contain cancer 
stem cells due to the flooding of NK cells by prolifer-
ating cancer stem cells and conversion of NK cells to 
cytokine secreting cells may likely be one mechanism 
by  which  cancer  may  progress  and  metastasize. 
Therefore, there should be two distinct strategies by 
the NK cells to eliminate tumors, one which targets 
stem cells and the other which targets differentiated 
cells. Since cancer stem cells were found to be more 
resistant to certain chemotherapeutic drugs but sensi-
tive to NK cell mediated killing while differentiated 
oral tumors were more resistant to NK cell mediated 
killing  but  relatively  more  sensitive  to  chemothera-
peutic drugs, combination therapy should be consid-
ered for the elimination of both undifferentiated and 
differentiated tumors. In addition, since a great ma-
jority of patient NK cells have modified their pheno-
type to support differentiation of the cells, they may 
not be effective in eliminating the cancer stem cells. 
Therefore, these patients may benefit from repeated 
allogeneic  NK  cell  transplantation  at  the  site  of  the 
tumor for elimination of cancer stem cells. In this re-
gard depletion of immunosuppressive effectors in the 
tumor microenvironment, which condition NK cells 
to lose cytotoxicity, via radiation or chemotherapeutic 
drugs should in theory provide a better strategy for 
successful targeting of tumors by the NK cells. 
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